Sign inJoin waitlistJoin the waitlist

Todd Aguilera

Associate Professor · University of Texas Southwestern Medical Center

Credentials: · · · · ·

History

University of Texas Southwestern Medical Center
Present
University of Texas Southwestern Medical Center
Present

Radiation Oncology
Stanford University Medical Center (2012-
2016–2017
Stanford University Medical Center (2012-
2012–2016
Internal Medicine
University of California (San Diego) Medical Center
2011–2012
UC San Diego School of Medicine
2007–2011

Research

Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome
Science · 2009 · 518 citations
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Proceedings of the National Academy of Sciences of the United States of America · 2010 · 417 citations
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival
Proceedings of the National Academy of Sciences of the United States of America · 2010 · 358 citations

Nina Sanford
17 papers · 1 as a resident
Shaalan Beg
12 papers
Michael Folkert
11 papers
EO
Emilia Olson
7 papers · 2 as a resident
Herbert Zeh
7 papers
Robert Timmerman
7 papers
AS
Aravind Sanjeevaiah
6 papers
Patricio Polanco
6 papers
Raquibul Hannan
6 papers
AE
Ahmed Elamir
5 papers · 5 as a resident
Quyen Nguyen
5 papers
Albert Koong
4 papers

Grants

Early Response to Radiotherapy and Immunotherapy in Rectal Cancer: An Integrated Molecular, Cellular, and Spatial Approach
National Cancer Institute · R01
Contact PI · $2.6M · Ut Southwestern Medical Center
2023–2028

Clinical trials

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
Principal investigator · Completed · Phase 2
University of Texas Southwestern Medical Center
2020–2026
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2030
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Site PI · Recruiting · Phase 3
M.D. Anderson Cancer Center
2024–2029